Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Salbutamol sulfate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for What is Easyhaler Salbutamol? Easyhaler Salbutamol is a "reliever" inhaler. The active ingredient is salbutamol, an asthma medicine, which opens up the airways. Salbutamol has a quick effect and a short duration of action (4 to 6 hours). What is Easyhaler Salbutamol used for? Salbutamol is used to relieve symptoms of asthma and other asthma-like conditions such as chest tightness, wheezing and coughing in adults and children aged 4 years and over. It is also used for
prevention of asthma symptoms brought on by exercise or a known allergen exposure that cannot be avoided.
e Easyhaler Salbutamol Do not use Easyhaler Salbutamol:
Lactose contains small amounts of milk proteins, which may cause allergic reaction. If you have been told that you do not tolerate certain kinds of sugars, contact your doctor before taking this medicine. The amount of lactose in Easyhaler Salbutamol (less than 10 mg per dose) does not normally cause problems in lactose intolerant people. 3. How to use Easyhaler Salbutamol You will be shown how to use the Easyhaler by your doctor or asthma nurse. Always use this medicine exactly as your doctor or asthma nurse has told you. Check with your doctor or asthma nurse if you are not sure how to use the Easyhaler, how many puffs (actuations) to take or how often to take it. IMPORTANT-contact your doctor immediately if:
For regular treatment the dose is up to two puffs (200mcg) up to 4 times a day. Children should always have adult supervision when using the Easyhaler The maximum daily dose (in 24 hours) for both adults and children aged 4 years and over: 8 puffs of the 100 mcg (800 micrograms). The recommended dose for Easyhaler Salbutamol 200 mcg is: Adults, Older people and Adolescents aged 12 years and over: For the relief of symptoms of acute asthma attack and intermittent asthma the starting dose is one puff (200mcg) that may be increased to two puffs (400mcg). To prevent symptoms before exercise or contact with whatever triggers your asthma attack the starting dose is one puff (200mcg) that may be increased to two puffs (400mcg). Children aged 4 to 11 years: For the relief of symptoms of acute asthma attack and intermittent asthma the dose is one puff (200mcg) as required. To prevent symptoms before exercise or contact with whatever triggers your asthma attack the dose is one puff (200mcg). For regular treatment the dose is one puff (200mcg) up to 4 times a day. Children should always have adult supervision when using the Easyhaler The maximum daily dose (in 24 hours) for both adults and children: 4 puffs of the 200 mcg (800 micrograms). If you use more Easyhaler Salbutamol than you should If you have taken more puffs than recommended, you should contact your doctor immediately. You may notice that your heart is beating faster than usual and that you feel shaky. These effects usually wear off in a few hours. If you forget to use Easyhaler Salbutamol If you forget to take a dose do not worry. Take your next dose when it is due or if you become wheezy. Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. The instructions on how to use the inhaler are at the end of the leaflet.
CORRECTLY Step 1: SHAKE
SHAKE x 3-5
Important points to remember
Step 2: CLICK
CLICK x 1
Step 3: INHALE
Important points to remember
INHALE
Important points to remember
If you need to take another inhalation, please repeat the steps 1-3 Shake-Click-Inhale. After you have used the inhaler:
How to empty the powder from the mouthpiece If you click the inhaler by accident, or if you might have clicked it more than once, or if you breathe out into it, empty the mouthpiece.
Cleaning the Easyhaler Keep your inhaler dry and clean. If necessary you may wipe the mouthpiece of your inhaler with a dry cloth or tissue. Do not use water: the powder in the Easyhaler is sensitive to moisture. Using the Easyhaler with a protective cover You may use a protective cover with your inhaler. This helps to improve durability of the product. When you first insert your inhaler in the protective cover make sure the dustcap is on the inhaler as this stops it going off by accident. You can use the inhaler without removing it from the protective cover. Follow the same instructions as above, 1. Shake – 2. Click
When to switch to a new Easyhaler The dose counter shows the number of remaining doses. The counter turns after every 5th click. When the dose counter starts turning red, there are 20 doses left. If you do not already have a new Easyhaler, contact your doctor for a new prescription. When the counter reaches 0 (zero), you need to replace the Easyhaler. If you use the protective cover, you can keep it and insert your new inhaler into it.
Remember • •
1. Shake – 2. Click – 3. Inhale. Do not get your inhaler wet, protect it from moisture.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. If you experience any of the following side effects, stop taking Easyhaler Salbutamol and seek immediate medical attention:
Other side effects Common side effects (may affect up to 1 in 10 people)
Easyhaler Salbutamol
What Easyhaler Salbutamol contains
Easyhaler multidose powder inhaler contains 200 doses (puffs). Packages: 200 doses in plastic multidose powder inhaler 200 doses in plastic multidose powder inhaler and protective cover A protective cover is also available separately. Marketing Authorisation Holder Orion Corporation Orionintie 1 FIN-02200 Espoo Finland Manufacturer Orion Corporation, Orion Pharma Orionintie 1 02200 Espoo Finland
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Orion Pharma UK Ltd, 9th Floor, The Blade, Abbey Square, Reading, RG1 3BE Tel.: +44 1635 520 300 This leaflet was last revised in January 2026
Detailed and updated information on how to use this product is available by scanning this QR code (included also on outer carton and inhaler label) with a smartphone. The same information is also available on the following URL: www.oeh.fi/sgb. QR code to www.oeh.fi/sgb.
How to use the Easyhaler inhaler About your Easyhaler Easyhaler Salbutamol may be different to inhalers you have used in the past. Therefore it is very important that you use it properly as using incorrectly can lead to you not receiving the right amount of medicine. This could make you very unwell or could lead to your asthma not being treated as it should. Your doctor, nurse or pharmacist will show you how to use your inhaler properly. Make sure you understand the correct way to use the inhaler. If you are unsure contact your doctor, nurse or pharmacist. As with all inhalers, caregivers should ensure that children prescribed Easyhaler Salbutamol use correct inhalation technique, as described below. You can also use the instruction video at www.oeh.fi/sgb. When you first get your Easyhaler The Easyhaler comes in a foil bag. Do not open the foil bag until you are ready to start using the medicine as it helps to keep the powder dry in the inhaler. When you are ready to start treatment open the bag and record the date e.g., in your calendar. Use the inhaler within 6 months of removing from the foil bag.
The active substance in Easyhaler Salbutamol 100mcg is salbutamol sulfate.
Medicines with the same active substance, strength and form include: Ventolin Evohaler 100 micrograms. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Easyhaler Salbutamol 100mcg, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Symptomatic treatment of asthma attacks and exacerbations of asthma in adults and children aged 4 years and over. Prevention of exercise-induced bronchospasm or before exposure to a known unavoidable allergen challenge. Symptomatic treatment of broncho-asthma and other conditions associated with reversible airways obstruction.
Salbutamol provides a short-acting bronchodilation with fast onset of action in reversible airways obstruction due to asthma.
Easyhaler Salbutamol Sulfate should be used to relieve symptoms when they occur and to prevent them in those circumstances recognised by the patient to precipitate an attack (e.g. before exercise or unavoidable allergen exposure).
Salbutamol is valuable as a rescue medication in mild, moderate or severe asthma, provided that reliance on it does not delay the introduction and use of regular inhaled corticosteroid therapy.
Easyhaler Salbutamol Sulfate is indicated in adults, adolescents and children aged 4 to 11 years.
Posology
Adults and Older people:
For the relief of acute bronchospasm and for managing intermittent episodes of asthma, one inhalation (100 micrograms) may be administered as a single starting dose; this may be increased to two inhalations (200 micrograms) if necessary.
To prevent exercise-induced bronchospasm or allergen bronchospasm two inhalations (200 micrograms) should be taken before challenge, this dose (200 micrograms) may be repeated if necessary.
Paediatric Population:
Relief of acute bronchospasm
Children aged 4 to 11 years 100 micrograms as required. The dose may be increased to two inhalations if required.Children aged 12 years and over: Dose as per adult population.
Prevention of allergen or exercise-induced bronchospasm
Children aged 4 to 11 years 100 micrograms before challenge or exertion. The dose may be increased to two inhalations if required.Children aged 12 years and over: Dose as per adult population.
Chronic therapy
Children aged 4 to 11 years up to 200 micrograms four times a day. On-demand use of Easyhaler Salbutamol Sulfate should not exceed four times daily. Reliance on such frequent supplementary use, or a sudden increase in dose, indicates poorly controlled or deteriorating asthma (see section 4.4).
Children aged 12 years and over: Dose as per adult population.
On demand use of Easyhaler Salbutamol Sulfate should not exceed eight inhalations (800 micrograms) in any 24 hour period.
For optimum results in most patients Easyhaler Salbutamol Sulfate inhaler should be used regularly during asthmatic attacks. The bronchodilator effect of each administration of inhaled salbutamol lasts for four hours, except in patients whose asthma is becoming worse. Such patients should be warned not to increase their usage of salbutamol, but should seek medical advice in case treatment with an inhaled and/or systemic glucocorticosteroid is indicated.
Method of administration
For oral inhalation only.
This preparation is particularly useful for patients unable to use metered dose inhalers properly and for patients in whom the use of an inhalation aerosol causes irritation of airways. Inhaled salbutamol should be used only on as-needed basis at the lowest dose and frequency required.
Precautions to be taken before handling or administering the medicinal product
Instructions for use:
The protective cover of the inhaler should be opened and the dust cap removed immediately prior to use.
The inhaler should be shaken vigorously up and down 3-5 times. Whilst holding the inhaler in an upright position, between the finger and thumb, press once until a click is heard. Let inhaler click back again whilst continuing to hold in an upright position.
Inhalation should take place from either a sitting or standing position. The patient should breathe out normally and place the mouthpiece between their teeth whilst using their lips to form a seal around the mouthpiece. Patients are instructed to perform a rapid and forced inhalation through the Easyhaler device. After holding their breath for at least 5 seconds the patient can resume normal breathing. Patients should not to exhale into the device.
The mouthpiece of the inhaler should be cleaned once a week using a dry cloth or tissue.
Patients should be instructed in the proper use of their inhaler (see patient information leaflet) and children should always have adult supervision when using the device. Illustrated instructions for use accompany each package.
Hypersensitivity to salbutamol or to the excipient listed in section 6.1 (lactose monohydrate, which contains small amounts of milk proteins).
Salbutamol inhalation is contraindicated in treatment of threatened abortion or premature labour.
Patients who are prescribed regular anti-inflammatory therapy (e.g., inhaled corticosteroids) should be advised to continue taking their anti-inflammatory medication even when symptoms decrease, and they do not require Salbutamol.
Bronchodilators should not be the only or main treatment in patients with severe or unstable asthma.
Severe asthma requires regular medical assessment including lung function testing as the patients are at risk of severe attacks and even death. Physicians should consider using oral corticosteroid therapy or the maximum use of inhaled corticosteroids. Increasing use of bronchodilators, particularly short-acting inhaled ß2-agonists to relieve symptoms indicates deteriorating asthma control (especially if the peak expiratory flow rate value falls and/or becomes irregular), and patients should be warned to seek medical advice as soon as possible.
Overuse of short-acting beta-agonists may mask the progression of the underlying disease and contribute to deteriorating asthma control, leading to an increased risk of severe asthma exacerbations and mortality.
Patients who take more than twice a week “as needed” salbutamol, not counting prophylactic use prior to exercise, should be re-evaluated (i.e., daytime symptoms, night-time awakening, and activity limitation due to asthma) for proper treatment adjustment as these patients are at risk for overuse of salbutamol.
In the event of a previous effective dose of inhaled salbutamol failing to give relief for at least three hours or if they need more inhalations than usual, the patient should be advised to seek medical advice as soon as possible. In this situation patients should be reassessed and consideration given to an increase in their anti-inflammatory therapy, (e.g. higher doses of inhaled corticosteroids or a course of oral corticosteroids). A regular anti-inflammatory controller medication taken on a daily basis is required as soon as the patient needs inhaled ß2-agonists more than twice a week. Severe episodes of asthma must be treated in the normal way.
As there may be adverse effects associated with excessive dosing, the dosage and frequency of administration should only be increased on medical advice.
Salbutamol should be administered with caution in patients with thyrotoxicosis, cardiac insufficiency, hypokalaemia, myocardial ischaemia, tachyarrhythmia and hypertrophic obstructive cardiomyopathy.
Potentially serious hypokalaemia may result from ß2 agonist therapy, mainly from parenteral and nebulised therapy. Particular caution is advised in acute severe asthma, as this effect may be potentiated by concomitant treatment with xanthine derivatives, steroids, diuretics and by hypoxia. It is recommended that serum potassium levels are monitored in such situations (see section 4.5).
Rarely inhalation therapy may cause bronchospasm after dosing. In this event, treatment with Salbutamol must be immediately discontinued and, if need be, replaced with another therapy.
Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol. There is some evidence from post-marketing data and published literature of rare occurrences of myocardial ischaemia associated with salbutamol. Patients with underlying severe heart disease (e.g. ischaemic heart disease, arrhythmia or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease. Attention should be paid to assessment of symptoms such as dyspnoea and chest pain, as they may be of either respiratory or cardiac origin.
In common with other beta-adrenoceptor agonists, salbutamol can induce reversible metabolic changes such as increased blood glucose levels. Diabetic patients may be unable to compensate for the increase in blood glucose and the development of ketoacidosis has been reported. Concurrent administration of glucocorticoids can exaggerate this effect.
One dose contains less than 10 mg lactose, which probably does not cause symptoms in lactose intolerant patients. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
If additional adrenergic drugs are administered to patients using Salbutamol Easyhaler they should be used with caution to avoid deleterious cardiovascular effects.
Concomitant administration of salbutamol and non-selective ß-blocking drugs such as Propranolol is not recommended.
Patients treated with monoamine oxidase inhibitors or tricyclic antidepressants should be followed clinically in the beginning of salbutamol treatment, because the action of salbutamol on the vascular system may be potentiated.
The simultaneous administration of xanthines, corticosteroids or potassium excreting diuretics may increase hypokalaemia.
Pregnancy
Safety in pregnant women has not been established. No controlled clinical trials with salbutamol have been conducted in pregnant women. Rare reports of various congenital anomalies following intrauterine exposure to salbutamol (including cleft palate, limb defects and cardiac disorders) have been received. Some of the mothers were taking multiple medications during their pregnancies. Administration of drugs during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.
Breast-feeding
As salbutamol is excreted in breast milk, its use in nursing mothers requires careful consideration. It is not known whether salbutamol has a harmful effect on the neonate, and so its use should be restricted to situations where it is felt that the expected benefit to the mother outweighs any potential risk to the neonate.
Fertility
There is no information on the effects of salbutamol on human fertility.
Salbutamol Easyhaler has no or negligible influence on the ability to drive and use machines.
The undesirable effects caused by normally used inhaled doses of salbutamol are mild, typical for sympathomimetic agents, and they usually disappear with continued treatment.
Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common, (≥1/100 and <1/10), uncommon (≥1/1000 and <1/100), rare (≥1/10,000 and <1/1000), very rare (<1/10,000) and not known (cannot be estimated from the available data).
Common
Uncommon
Rare
Very Rare
Immune System disorders
hypersensitivity reactions (angioedema, urticaria, hypotension and collapse)
Metabolism and nutrition disorders
hypokalaemia
Nervous system disorders
Headache
hyperactivity, restlessness, dizziness
Sleep disturbances
Cardiac disorders
palpitations
myocardial ischaemia
Cardiac arrhythmias including atrial fibrillation, supraventricular tachycardia and extrasystoles
Vascular disorders
peripheral vasodilatation, and as a result small increase in heart rate
Respiratory, thoracic and mediastinal disorders
bronchospasm (see section 4.4), cough, irritation of mouth and throat which may be prevented by rinsing the mouth after inhalation.
Musculoskeletal and connective tissue and bone disorders:
tremor
muscle cramps,
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Excess repeat use of inhalations may produce adverse effects such as tachycardia, CNS stimulation, tremor, hypokalaemia and hyperglycaemia.
Lactic acidosis has been reported in association with high therapeutic doses as well as overdoses of short-acting beta-agonist therapy, therefore monitoring for elevated serum lactate and consequent metabolic acidosis (particularly if there is persistence or worsening of tachypnea despite resolution of other signs of bronchospasm such as wheezing) may be indicated in the setting of overdose.
Treatment consists of discontinuation of salbutamol together with appropriate symptomatic therapy. The preferred antidote for overdosage with salbutamol is a cardioselective beta-blocking agent, but beta-blocking drugs should be used with caution in patients with a history of bronchospasm. Hypokalaemia may occur following overdose with salbutamol. Serum potassium levels should be monitored. If hypokalaemia occurs potassium replacement via the oral route should be given. In patients with severe hypokalaemia intravenous replacement may be necessary.
Ask anything about Easyhaler Salbutamol 100mcg. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.